EDITORIAL

Metabolic disorders during pregnancy and postpartum cardiometabolic risk

Angelo Maria Patti¹, Kalliopi Pafili², Nikolaos Papanas² and Manfredi Rizzo¹

¹Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
²Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece

Correspondence should be addressed to A M Patti: pattiangelomaria@gmail.com

Abstract

Hormonal changes during pregnancy can trigger gestational diabetes (GDM), which is constantly increasing. Its main characteristic is pronounced insulin resistance, but it appears to be a multifactorial process involving several metabolic factors; taken together, the latter leads to silent or clinically evident cardiovascular (CV) events. Insulin resistance and central adiposity are of crucial importance in the development of metabolic syndrome, and they appear to correlate with CV risk factors, including hypertension and atherogenic dyslipidaemia. Hypertensive disease of pregnancy (HDP) is more likely to be an accompanying co-morbidity in pregnancies complicated with GDM. There is still inconsistent evidence as to whether or not co-existent GDM and HDP have a synergistic effects on postpartum risk of cardiometabolic disease; however, this synergism is becoming more accepted since both these conditions may promote endothelial inflammation and early atherosclerosis. Regardless of the presence or absence of the synergism between GDM and HDP, these conditions need to be dealt early enough, in order to reduce CV morbidity and to improve health outcomes for both women and their offspring.

Introduction

There are several pregnancy indices of hormonal changes (such as oestrogens, progesterone, corticotropin-releasing hormone, cortisol, human placental growth hormone and human placental lactogen) that are implicated in the development of gestational diabetes (GDM) cases (1). Epidemiological evidence has consistently shown that among mothers with prior history of GDM, 30–84% of them had GDM recurrence in subsequent pregnancies (2), 20–40% developed metabolic syndrome (MetS) within 2–20 years (3, 4) and 17–63% developed type 2 diabetes mellitus (T2DM) and obesity within 5–16 years (5, 6, 7). Longitudinal studies have shown that women with prior GDM and obesity were at higher risk to develop MetS compared with those without such metabolic history (8), and these women with prior GDM and obesity had relatively higher values of anthropometric parameters (such as BMI and waist circumference), blood pressure, glucose, homeostatic model assessment, insulin, C-peptide and fibrinogen, together with lower HDL-C levels (9).

Insulin resistance and central adiposity are of crucial importance in the development of MetS, and they appear to correlate with cardiovascular (CV) risk factors, including hypertension, atherogenic dyslipidaemia and glucose intolerance. The underlying mechanism of GDM is mainly pronounced insulin resistance (1). However, other factors, such as race, ethnicity, environmental and genetic factors (10), appear to contribute to the development of silent or clinical CV events. Interestingly, hypertensive disease of pregnancy (HDP) is very likely to be an accompanying co-morbidity in pregnancies

Key Words
- cardiovascular risk
- gestational diabetes
- hypertension
- metabolic syndrome
complicated with GDM (11, 12, 13). Indeed, both these gestational complications share common risk factors such as maternal age, parity and pre-pregnancy BMI. Arguably, they may also share underlying mechanisms predisposing to subsequent recurrence of pregnancy complications and postpartum cardiometabolic disorders (14, 15, 16, 17, 18).

However, it may also be true that HDP and GDM are the result of inherent susceptibility to cardiovascular disease (CVD). Mothers who were obese or had a personal history of chronic hypertension or diabetes before pregnancy are more likely to develop HDP or GDM (19, 20, 21), and family history of CV risk is closely related to future CVD (22, 23).

**Is there a synergistic effect of GDM and HDP on postpartum cardiometabolic risk?**

It has been reported that there is a significant link between pregnancy complications (GDM and HDP) and CVD later in life (18, 24), since HDP and GDM may promote endothelial inflammation and early atherosclerosis independently of underlying conditions (25, 26, 27, 28, 29, 30). HDP and GDM also negatively impact on inflammatory biomarkers, including higher levels of plasminogen activator inhibitor-1, adiponectin, C-reactive protein, leptin and TNF alpha (1, 14). Importantly, these inflammatory biomarkers play an important role beyond their role in diabetes, insulin resistance, visceral obesity, CVD and hypertension (32, 33). Moreover, GDM and HDP are linked with elevated LDL-C and small dense LDL particles, which are implicated in CVD (31, 34).

Even though GDM and HDP may co-exist in pregnancies of the same mothers and are associated with CV risk, some controversy remains as to whether or not co-existent GDM and HDP have a synergistic effect to the risk of postpartum cardiometabolic disease (13). GDM or HDP is associated with a 15-fold higher risk in postpartum diabetes, with a sixfold greater risk of postpartum hypertension and a 40% risk increase for CVD mortality in the mothers (35). Meta-analyses have demonstrated that GDM is associated with a sevenfold higher risk of T2DM in affected mothers, and HDP is associated with a double risk of postpartum diabetes (5, 26). It has also been shown that a prior GDM can enhance the risk of having not only T2DM but also CVD, independently (36).

Interestingly, the study of Li *et al.* (37) shows that GMD and HDP contribute independently and not synergistically to the postpartum cardiometabolic risk, and this was somewhat unexpected, given the accumulating evidence (35, 36, 37) that suggest that these conditions interplay in increasing the risk of diabetes, hypertension and CVD later in the mothers’ lives as well as in their offspring (10, 26, 38). There are some potential limitations in the study of Li *et al.* that need to be briefly discussed (37). First, the small cohort of subjects and the relative brief follow-up period. In addition, GDM cases may be somewhat misclassified because the diabetes diagnosis required fasting and/or the 2-h glucose testing after a 75 g oral glucose intake. Further, the data on GDM and HDP history were based on self-reports only. Finally, as already highlighted by the authors, since some mothers with an episode of GMD and/or HDP did not or were not able to conceive, subsequently, these findings could have underestimated their risks.

It is well known in literature that women with GMD and HDP are more prone to MetS (39, 40, 41), and they appear to transmit an increased risk to the offspring through vertical transmission (8). Thus, it seems that women with GMD and HDP create an adverse metabolic memory (42).

**Conclusion**

Women who have had GDM and/or HDP are now recognised to carry a high risk of CVD and, regardless of the presence or absence of the synergism between GMD and HDP, they need to be followed very carefully. Indeed, the American Heart Association recommends long-term surveillance and management of CV risk factors in women with these pregnancy-related complications (43, 44). Of note, many women with GDM have later in life an undiagnosed T2DM (45) and, therefore, increased awareness of GMD and HDP is needed. In addition, postpartum screening tools and biomarkers of subsequent risk are very helpful in long-term follow-up.

**Declaration of interest**

All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this editorial. This editorial was written independently. The authors have given talks, attended conferences and participated in advisory boards and trials sponsored by various pharmaceutical companies.

---

http://www.endocrineconnections.org
https://doi.org/10.1530/EC-18-0130
© 2018 The authors
Published by Bioscientifica Ltd
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Funding
This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References
1 Ben-Haroush A, Yogev Y & Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabetic Medicine 2004 21 103–113. (https://doi.org/10.1046/j.1464-5412.2003.00985.x)
2 Kim C, Berger DK & Chamany S. Recurrence of gestational diabetes mellitus: a systematic review. Diabetes Care 2007 30 1314–1319. (https://doi.org/10.2337/dc07-0517)
3 Gunderson EF, Jacobs DR, Jr, Chiang V, Lewis CE, Feng J, Quesenberry CP Jr & Sidney S. Duration of lactation and incidence of the metabolic syndrome in women of reproductive age according to gestational diabetes mellitus status: a 20-year prospective study in CARDIA (Coronary Artery Risk Development in Young Adults). Diabetes 2010 59 495–504. (https://doi.org/10.2337/db09-1197)
4 Lauenborg J, Mathiesen E, Hansen T, Glümer C, Jørgensen T, Borch-Johnsen K, Hornnes P, Pedersen O & Damm P. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. Journal of Clinical Endocrinology and Metabolism 2005 90 4004–4010. (https://doi.org/10.1210/jc.2004-1713)
5 Bellamy L, Casas JP, Hingorani AD & Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009 373 1773–1779. (https://doi.org/10.1016/S0140-6736(09)60731-5)
6 Hanna FW & Peters JR. Screening for gestational diabetes; past, present and future. Diabetic Medicine 2002 19 351–358. (https://doi.org/10.1046/j.1464-5491.2002.00664.x)
7 Lee AJ, Hiscock RJ, Wein P, Walker SP & Permezel M. Gestational diabetes mellitus: clinical predictors and long-term risk of developing type 2 diabetes: a retrospective cohort study using survival analysis. Diabetes Care 2007 30 878–883. (https://doi.org/10.2337/dc07-1816)
8 Malcolm J. Through the looking glass: gestational diabetes as a predictor of maternal and offspring long-term health. Diabetes/Metabolism Research and Reviews 2012 28 307–311. (https://doi.org/10.1002/dmrr.2275)
9 Bo S, Monge L, Macchetta C, Menato G, Pinach S, Uberti B & Mathiesen ER & Clausen TD. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Diabetologia 2016 59 1396–1399. (https://doi.org/10.1007/s00125-016-3985-8)
10 Rizvi AA, Cuadra S, Nikolic D, Giglio RV, Montalto G & Rizzo M. Family history of hypertension and type 2 diabetes mellitus in a Portuguese population. Human Population Genetics 2013 201 367–372. (https://doi.org/10.1007/s12343-013-0224-3)
11 Romundstad PR, Magnussen EB, Smith GD & Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010 122 579–584. (https://doi.org/10.1161/CIRCULATIONAHA.110.943407)
12 Qin C, Williams MA, Leisneming WM, Sorensen TK, Frederik IO, Demspye JC & Lathy DA. Family history of hypertension and type 2 diabetes in relation to preeclampsia risk. Hypertension 2003 41 408–413. (https://doi.org/10.1161/01.HYP.0000065696.25503.F5)
13 Ehrenthal DB, Maiden K, Rogers S & Ball A. Postpartum healthcare outcomes. International Journal of Gynaecology and Obstetrics 2015 139 239–249. (https://doi.org/10.1016/j.ijgo.2014.12.008)
15 Vambergue A, Nuttens MC, Goesaert F, Blauzeque S, Lepetit M & Fontaine P. Pregnancy induced hypertension in women with gestational carbohydrate intolerance: the diagast study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2002 102 31–35. (https://doi.org/10.1016/S0301-2115(01)00556-5)
16 Damm P, Houshmand-Oreaga A, Kelstrup L, Lauenborg J, Mathiesen ER & Clausen TD. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Diabetologia 2016 59 1396–1399. (https://doi.org/10.1007/s00125-016-3985-8)
17 Gongora MC & Wenger NK. Cardiovascular complications of pregnancy. International Journal of Molecular Sciences 2015 16 23905–23928. (https://doi.org/10.3390/ijms161023905)
18 Naderi S, Tsai SA & Khandelwal A. Hypertensive disorders of pregnancy. Current Atherosclerosis Reports 2017 19 15. (https://doi.org/10.1007/s11883-017-0648-z)
19 D'Agostino RB Sr, Vasan RS, Levy D, Belanger AM, Silbershatz H & Kannel WB. Prediction of coronary heart disease risk: universal definition. Circulation 2008 117 1060–1061. (https://doi.org/10.1161/CIRCULATIONAHA.107.729213)
20 Qiu C, Williams MA, Leisneming WM, Sorensen TK, Frederik IO, Demspye JC & Lathy DA. Family history of hypertension and type 2 diabetes in relation to preeclampsia risk. Hypertension 2003 41 408–413. (https://doi.org/10.1161/01.HYP.0000065696.25503.F5)
21 D'Agostino Jr, foreclosure, type 2 diabetes mellitus and cardiovascular risk among women with preeclampsia. Diabetes Care 2007 30 235–239. (https://doi.org/10.2337/dc07-0222)
22 D'Agostino RB Sr, Vasan RS, Levy D, Belanger AM, Silbershatz H & Kannel WB. Prediction of coronary heart disease risk: universal definition. Circulation 2008 117 1060–1061. (https://doi.org/10.1161/CIRCULATIONAHA.107.729213)
30. Mizak I, Arfa A, Fekih M, Debbabi H, Bouslama A, Boumaiza I, Zaouali M, Khan NA & Tahla Z. Inflammation and impaired endothelium-dependant vasodilatation in non obese women with gestational diabetes mellitus: preliminary results. *Lipids in Health and Disease* 2013 **12** 92. (https://doi.org/10.1186/1476-511X-12-93)

31. Qiu C, Rudra C, Austin MA & Williams MA. Association of gestational diabetes mellitus and low-density lipoprotein (LDL) particle size. *Physiological Research* 2007 **56** 571–578.

32. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. *Nutrition Reviews* 2007 **65** 253–259. (https://doi.org/10.1301/nr.2007.dec.S253-S259)

33. Rizvi AA. Hypertension, obesity, and inflammation: the complex consequences of gestational dysglycemia. *Seminars in Reproductive Medicine* 2013 **31** 247–54. (https://doi.org/10.1055/s-0033-1342901)

34. Brewster S, Zinman B, Retnakaran R & Floras JS. Cardiometabolic disease in parents: a retrospective cohort study. *American Journal of Epidemiology* 2017 **186** 1115–1124. (https://doi.org/10.1093/aje/kwx263)

35. Pace R, Brazeau AS, Meltzer S, Rahme E & Dasgupta K. Conjoint associations of gestational diabetes and hypertension with diabetes, hypertension, and cardiovascular disease in parents: a retrospective cohort study. *American Journal of Epidemiology* 2017 **186** 1115–1124. (https://doi.org/10.1093/aje/kwx263)

36. Bentley-Lewis R. Late cardiovascular consequences of gestational diabetes mellitus. *Seminars in Reproductive Medicine* 2009 **27** 322–329. (https://doi.org/10.1055/s-0029-1225260)

37. Li LJ, Aris IM, Su LL, Chong YS, Wong TY, Tan KH & Wang JJ. Effect of gestational diabetes and hypertensive disorders of pregnancy on postpartum cardiometabolic risk. *Endocrine Connections* 2018 **7** 433–442. (https://doi.org/10.1530/EC-17-0359)

38. Nolan CJ, Damm P & Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. *Lancet* 2011 **378** 169–181. (https://doi.org/10.1016/S0140-6736(11)60614-4)

39. Sim JH, Chung D, Lim JS, Lee MY, Chung CH, Shin JY & Huh JH. Maternal age at first delivery is associated with the risk of metabolic syndrome in postmenopausal women: from 2008–2010 Korean National Health and Nutrition Examination Survey. *PLoS ONE* 2015 **10** e0127860. (https://doi.org/10.1371/journal.pone.0127860)

40. Sullivan SD, Umans JG & Ratner R. Gestational diabetes: implications for cardiovascular health. *Current Diabetes Reports* 2012 **12** 43–52. (https://doi.org/10.1007/s11892-011-0238-3)

41. Rizzo M, Berneis K, Altinova AE, Toruner FB, Akturk M, Ayvaz G, Rini GB, Spinas GA & Arslan M. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes. *Diabetic Medicine* 2008 **25** 1406–1411. (https://doi.org/10.1111/j.1464-5491.2008.02613.x)

42. Yessoufou A & Moutairou K. Maternal diabetes in pregnancy: early and long-term outcomes on the offspring and the concept of ‘metabolic memory’. *Experimental Diabetes Research* 2011 **2011** 218598. (https://doi.org/10.1155/2011/218598)

43. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenland K, Daniels S, Nichol G, Tomasselli GF, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. *Circulation* 2010 **121** 586–613. (https://doi.org/10.1161/CIR.0b013e3181fd443e)

44. Mosca L, Benjamin EJ, Berra K, Bezasnon JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. *Circulation* 2011 **123** 1243–1262. (https://doi.org/10.1161/CIR.0b013e31820f9a48)

45. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva AD, Hod M, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010 **33** 676–682. (https://doi.org/10.2337/dc09-1848)